Skip to Main Content

On Monday, Editas Medicines announced that veteran biopharma executive James “Jim” Mullen was expanding his role with the gene-editing biotech, taking over as the new CEO while continuing as the company’s chairman — a role he’s held since March 2018.

Mullen replaces Cynthia Collins, who became Editas’ CEO in August 2019.


STAT spoke to Mullen about his decision to take over and his vision for the company, which is using the CRISPR gene-editing technology to develop treatments for rare, inherited diseases. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!